PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental 'Triple-Target' drug tested for stubborn autoimmune illnesses
Disease control Recruiting nowThis early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advan…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New blood disorder treatment aims to boost platelets fast
Disease control Recruiting nowThis study is testing a 5-day intravenous immunoglobulin (IVIG) treatment for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. The goal is to see if this treatment can safely and effectively raise …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New injection tested for rare bleeding disorder
Disease control Recruiting nowThis early-stage study is testing the safety and side effects of a single injection called PN20 in adults with chronic immune thrombocytopenia (ITP), a condition where the body attacks its own platelets. The main goal is to see if PN20 is safe for these patients and if it might h…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New treatment trial aims to boost platelets in chronic blood disorder
Disease control Recruiting nowThis Phase 3 study is testing whether an intravenous medication called efgartigimod can safely and effectively raise and maintain platelet counts in adults with chronic primary immune thrombocytopenia (ITP). About 69 participants will be randomly assigned to receive either the st…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New shot tested to boost platelets in blood disorder
Disease control Recruiting nowThis study is testing a new injectable drug called STSA-1301 for people with a chronic immune disorder that causes low platelet counts (ITP). The main goals are to check if the drug is safe and to see if it can help raise and maintain platelet levels. It will involve both healthy…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC